Comprehensive Scientific Analysis: Intermittent Fasting, GLP-1 Drugs & Expert Opinions
📅 Compiled: February 23, 2026 | 🏥 Sources: PubMed, PMC, ClinicalTrials.gov
Key Finding: IF induces metabolism of fatty acids to ketones, leading to weight decrease and improvements in dyslipidemia and blood pressure.
Core Theory: Insulin resistance is the root cause of obesity, not calories.
"The fastest way to dramatically lower your insulin levels is to simply stop eating."
Study Design: 174 participants, 8 weeks, 25% calorie restriction in both groups
| Metric | TRE (16:8) | 6 Meals/Day | Winner |
|---|---|---|---|
| Weight Loss | 1.17 kg MORE | Baseline | ✓ TRE |
| LDL Reduction | Improved | SUPERIOR | ✓ 6 Meals |
| Drug | Generic | Type | Avg Weight Loss |
|---|---|---|---|
| Ozempic | Semaglutide | GLP-1 agonist | 15% body weight |
| Mounjaro | Tirzepatide | Dual GIP/GLP-1 | 20%+ body weight |
Current Recommendation: NOT without medical supervision
Comparing TRE vs GLP-1 drugs vs combination approach
| Approach | Weight Loss | Cost | Sustainability |
|---|---|---|---|
| TRE (16:8) | Moderate (5-8%) | FREE | High |
| 6 Meals/Day | Moderate (4-6%) | FREE | Low-Medium |
| GLP-1 Drugs | High (15-20%) | $$$ ($1000+/mo) | Medium |